Airsonett Air4: Homebased treatment using Temperature Laminar airflow to treat allergic asthma and eczema (#2093)

Idea Description
Supplementary Information
Detailed Submission Data
Innovation 'Elevator Pitch':
Half a million adults and children in the UK experience severe asthma symptoms despite high dose medication. Air4 offers a non pharmacological treatment of allergic disease using Temperature Laminar Airflow to reduce exposure to allergens in the bed.
Overview of Innovation:
Air4 is a unique, innovative medical device which uses Temperture Laminar Airflow (TLA) technology to protect patients with severe allergic asthma and eczema, from exposure to allergens and other airborne particles (pollens, housedust mite and animal danders etc.) that are in and around the bed at night whilst they sleep. The device has no side effects and can therefore be used for adults and children.

Air4 is installed in the bedroom alongside the bed; air is drawn in the device from the room where it is filtered and cooled to 0.5-0.8 degrees centigrade lower than the ambient temperature. As cool air is heavier than room temperature, gravity ensures the air gradually descends without an excessive breeze or draught creating the patients breathing zone; due to the density of the air in the breathing zone airborne allergens are unable to penetrate and therefore the patient sleeps in an allergen free zone.

In reducing the airborne allergens the device has shown in clinical trials that is has reduced exacerbations and the number of hosptial admissions; it has reduced day and night time symptoms in patients and improved quality of life (health related) and has shown to reduce the number of days off work/school.

Air4 has a Medical Technology Innovation briefing from NICE stating the device is clinically and cost effective.There is also an Innovation Medical Technology Overview  from Helath Improve Scotland showing the device is clinically and cost effective compared to standard treatment.

Using the Air4 in adults or children who are still symptomatic despite maximum inhaler treatment; can avoid long term side effects from oral corticosteroids as well as the regular hospital visits from other treatmenst

Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
Similar Content1
Innovation 'Elevator Pitch':
Smartinhaler™ is an innovative electronic medication sensor that improves suboptimal medication use in patients with chronic respiratory diseases, including asthma and COPD. Our current focus is in asthma.
Overview of Innovation:
Poor medication adherence is one of the leading issues in the management of asthma and is thought to account for 34% of all asthma deaths (Royal College of Physicians, 2014) and treatment adherence to inhaled corticosteroids could reduce hospitalisation by 60% (Williams et al., 2004).
Smartinhaler™ (by Adherium Ltd) is a digital health solution to improve medication adherence in patients with chronic respiratory diseases. This is how it works: Smartinhaler™ clips onto an existing prescription inhaler. Once installed, the Smartinhaler™ device (1) periodically remind patients to take their medication, (2) records the date and time of inhaler use (independent of patient action), (3) transmits patient usage data to a mobile device and into Adherium’s cloud-based servers for patients and/or clinicians to review, and (4) provides warnings when the data indicate the patient’s disease may be escaping control.
The benefits of the Smartinhaler™ have been validated by independent clinical research. Four randomised controlled trials have shown consistent improvement in asthma medication adherence, ranging from 144% to 180% in children (Chan et al., 2015; Morton et al. 201X) and 33.3% to 58.7% in adults (Charles et al. 2007; Foster et al., 2014). Subsequently, the three studies measuring clinical outcome have demonstrated improved patient health as indicated by a reduction in oral corticosteroid use, reliever medication use, emergency room visits, lost school days and asthma morbidity score (Foster et al., 2014; Chan et al., 2015; Morton et al., 201X).
Audiovisual reminders markedly improve adherence to inhaled corticosteroids and thus increase health outcomes, whilst tracking reliever use may allow early detection of severe exacerbations (Patel et al., 2015). Furthermore, the objective nature of electronic adherence data enables an open and honest discussion about adherence and the barriers encountered by the patient. In turn, through HCP (or parental) intervention, this results in practical solutions to better manage asthma and or COPD.
The Smartinhaler™ platform was designed with patients in mind. In the development of the Smartinhaler, we’ve consulted patients and medical professionals to produce a user-centred system that facilitates good medical practice as well as empowering the patient.
For a list of references please visit our website:
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Potential reduction in mortality, hospital admissions, hospitalisations and A&E visits: Asthma accounts for approximately 60,000 hospital admissions and 200,000 bed days a year, with many others visiting A&E clinics without stay, uncontrolled asthma places a significant burden on NHS (British Lung Foundation, 2016). Williams et al. (2004) suggest adherence to inhaled corticosteroids could reduce hospitalisation by 60%. Given Smartinhaler’s ability to significantly and consistently improve adherence, it is expected that implementation of Smartinhalers™ will reduce the burden on the health services and most importantly improve the quality of life for asthmatics.
Potential reduction in medication wastage: In the UK, more than £230 million worth of asthma medicines are returned to pharmacies every year with a significantly larger proportion thought to be disposed by the patients themselves (Horne, 2006). Smartinhalers™ may reduce this wastage by improving treatment adherence as well as facilitating an open discussion about treatment between the clinicians, parents and patients.
Currently, the only similar technology implemented by some NHS funded hospitals is Florence – a telehealth application that connects patient data to healthcare professionals and text messaging to encourage positive behavioural change in patients with chronic illnesses. Although medication reminders can be sent to the phone, it appears text message reminders are less effective than direct device reminders (such as those in the Smartinhaler™) (Strandbygaard et al. 2010; Petrie et al. 2012). Furthermore, objective data about medication adherence cannot be collected using Florence and thus does not allow data-based clinical decisions for asthma. To our knowledge, there is no similar or equivalent technology used in current NHS practice specific for asthma. Standard physician care, asthma action sheets and for children, parental care, is the extent to which asthma medication adherence is addressed by the NHS. The Smartinhaler™ device would work alongside the current systems, used as an additional tool to improve the health of asthmatics, seamlessly integrating with current NHS practice.  
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Asthma is a major health issue in West Midlands. West Midlands (and South East) had the highest mortality rate for asthma. Furthermore, West Midlands has one of the highest asthma-related hospital admissions in England; in 2008-12, West Midlands was considered one of the worst five regions of England for asthma related admissions; other regions included North East, North West, and Yorkshire and the Humber (British Lung Foundation, 2016). Asthma not only influences health, it is associated with significant cost to society including work and school absenteeism as well as loss of productivity while at work (Bahadori et al. 2009).  
Taken together, introducing innovative and cost-effective digital health solutions is pivotal to the improvement of the health of West Midland’s asthmatics in increasing the quality of life, reducing burden on health services, and increasing economic productivity. As such, the implementation of Smartinhalers™ is a step forward for West Midlands health care system to alleviate the burden of asthma. 
Bahadori et al. (2009). Economic burden of asthma: a systematic review. BMC pulmonary medicine, 9(1), 1.
British Lung Foundation (2016). Retrieved from
Current and planned activity: 
  • Expansion of clinical data: several large and small clinical trials using Smartinhalers in asthma and COPD are on-going or in the prepublication stage. We expect more clinical trial results to be published this year and in the years ahead.
  • Development of new devices and further improvement of existing devices
  • Further improve patient-centred design of the Smartinhaler’s user interface
  • Expansion of global regulatory approvals
What is the intellectual property status of your innovation?:

Adherium has various patent protection in numerous jurisdictions. Furthermore, we hold numerous trademarks and registered design rights for our Smartinhaler™ range.
Return on Investment (£ Value): 
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Read more
Hide details

Created by

Share and Follow